Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...

Bioequivalence Data: Statistical Interpretation

Bioequivalence Data: Statistical Interpretation

The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...

Bioequivalence: Overview

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...

Equivalence: In Vitro and In Vivo Bioequivalence

Equivalence: In Vitro and In Vivo Bioequivalence

Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts. Pharmaceutical...

Bioavailability Study Design: Absolute Versus Relative Bioavailability

Bioavailability Study Design: Absolute Versus Relative Bioavailability

Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Optimal Weighted Tests for Replication Studies and the 'Two-Trials Rule' With Multiple Hypotheses.

Statistics in medicine·2026

Same author

A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection.

The Journal of antimicrobial chemotherapy·2026

Same author

Long-Term Integrated Safety and Efficacy of Garadacimab for Hereditary Angioedema Prophylaxis.

Advances in therapy·2026

Same author

An evaluation of designs for Phase I/IIa dose-finding studies in Tuberculosis.

Statistical methods in medical research·2026

Same author

Modern Clinical Trials: Seamless Designs and Master Protocols.

Cancer medicine·2026

Same author

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study.

Clinical pharmacology and therapeutics·2026

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Published on: October 17, 2025

Establishing bioequivalence in complete and incomplete data designs using AUCs.

Thomas Jaki¹, Martin J Wolfsegger, John-Philip Lawo

¹Department of Mathematics and Statistics, Lancaster University, Lancaster, United Kingdom. jaki.thomas@gmail.com

Journal of Biopharmaceutical Statistics

|May 25, 2010

Summary

This study compares bioequivalence assessment methods for drug pharmacokinetics in animals. It introduces new methods for small animals with limited sampling, optimizing study designs and sample sizes.

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Related Experiment Videos

Last Updated: Jun 12, 2026

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Published on: October 17, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Area of Science:

Pharmacokinetics
Drug Development
Bioequivalence Studies

Background:

Nonclinical in vivo animal studies are essential before human pharmacokinetic trials.
Drug exposure is commonly quantified using the area under the concentration-time curve (AUC).
Traditional complete data designs are impractical for small animals due to restricted blood sampling.

Purpose of the Study:

To derive the asymptotic distribution for the ratio of two AUCs.
To construct and evaluate confidence intervals for bioequivalence assessment.
To compare the performance and sample size requirements of different sampling designs (batch vs. serial) in small animals.

Main Methods:

Derivation of asymptotic distribution for AUC ratio.
Construction of confidence intervals for bioequivalence.
Simulation study to evaluate interval performance across designs.
Comparison of sample size needs for batch and serial sampling designs.

Main Results:

The study provides a framework for AUC ratio analysis in small animal pharmacokinetic studies.
Performance evaluation of different confidence intervals under various sampling designs.
Comparative analysis of sample size efficiency between batch and serial sampling.

Conclusions:

The findings offer guidance on selecting appropriate sampling designs for small animal pharmacokinetic studies.
The research contributes to optimizing bioequivalence assessments in preclinical drug development.
This work aids in determining efficient sample sizes for cost-effective animal studies.